Scientists have adapted the genetic modification technology CRISPR to identify antibodies in blood samples from patients in an attempt to encourage new grades of medical diagnostics along with a series of other applications.
The development of methods and miniaturized systems for fast and reliable quantitative determinations at the Point-of-Care is a top challenge and priority in diagnostics. In this work, a compact bench-top system, based on White Light Reflectance Spectroscopy, is introduced and evaluated in an…
/PRNewswire/ — BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced the launch of a new benchtop cell…
In 2020, three of the top 10 most searched terms were, unsurprisingly, healthcare-related. (Coronavirus, coronavirus update, coronavirus symptoms.) We’ve never been so attuned to what’s happening in our healthcare systems and hospitals.
Medical device company Medovate has successfully secured additional CE mark regulatory approvals for its SAFIRA (SAFer Injection for Regional Anaesthesia) technology to include an NRFit syringe and a Palm Operator.
Artificial intelligence specialist Caption Health gains Medicare coverage for ultrasound platform Matt O’Connor | August 09, 2021 | Cardiovascular Photo by Pavel Danilyuk via Pexels Artificial intelligence specialist Caption Health has been granted Medicare coverage for its ultrasound acquisition platform, the company announced Monday. The Brisbane, California-based organization says the new technology add-on payment from CMS will expand access to Caption Guidance, a “key” diagnostic tool for hospital inpatient care. The NTAP designation was implemented to support quick adoption of new medical technologies expected to substantially help Medicare patients. Reimbursement will go into effect Oct. 1 and cover ultrasound acquisitions for 461 diagnostic resource groups. These include heart failure, stroke and other common cardiovascular concerns. “With the NTAP approval, America’s vulnerable senior population will have greater access to innovative AI-based guidance and interpretation technologies from Caption, which means ultrasound testing can be utilized as needed, offering the potential to positively impact treatment and outcomes,” CEO Steve Cashman said Monday. Caption AI, which includes Caption Guidance, is the first and only FDA-cleared AI imaging software of its kind for cardiac ultrasound, the company said. Officials did not indicate a potential dollar amount for reimbursement, but Caption said payments “could be significant” for hospitals, depending on costs and clinical situation. For example, providers using Viz.ai’s stroke CT platform are eligible for up to $1,040 per patient under its recently renewed NTAP determination. “We are on a mission to expand access to ultrasound diagnosis and have already made strides through enabling a broader set of care team members to acquire diagnostic quality ultrasound studies,” Cashman added in a statement. “This NTAP designation helps to build upon that.” Email this author | Share by email Around the web RADIOLOGY BUSINESS Northwell Health experts believe their findings offer key clues as practices navigate subsequent stages of the public health crisis. RADIOLOGY BUSINESS Average payment for the first year of therapy landed at $11,975 for imaging-guided percutaneous ablation, nearly half of surgery’s tally, experts wrote in Academic Radiology. HEALTH EXEC Two out of three people have had a negative experience with a medical provider, according to a recent survey from Accenture. RELATED ARTICLES ON CARDIOVASCULAR, DIAGNOSTIC & SCREENING
Medical devices and medical software are becoming increasingly connected to hospital networks, other medical devices or the Internet. As a result, manufacturers and developers are required to consider cybersecurity from the very early stages of development.
Frequent, rapid testing for COVID-19 is critical to controlling the spread of outbreaks, especially as new, more transmissible variants emerge.
Engineers and ophthalmologists at Duke University have developed a robotic imaging tool that can automatically detect and scan a patient’s eyes for markers of different eye diseases.
DiaCarta, a molecular diagnostics company and developer of oncology tests using liquid biopsy has received CE/IVD marking for its new QuantiVirus SARS-CoV-2 Variant Detection Test.